Close Menu

NEW YORK — The US Food and Drug Administration has granted separate Emergency Use Authorizations for SARS-CoV-2 tests developed by Gencurix and Laihe Biotech.

Gencurix' GenePro SARS-CoV-2 Test is designed to detect the virus' Orf1-ab and RdRP genes in nasopharyngeal swab samples. It runs on Thermo Fisher Scientific's Applied Biosystems QuantStudio Dx RT-PCR instrument or Bio-Rad's CFX96 RT-PCR system, and can be used with 384-well plates, according to the company. Based in Seoul, South Korea, Gencurix develops molecular diagnostics.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.